Sareum Hldgs Plc (SAR) - Stock Price & Dividends
Exchange: London Exchange • Country: United Kingdom • Currency: GBX • Type: Common Stock • ISIN: GB00BMC3RJ87
Sareum Holdings plc is a company focused on developing therapeutic drugs for cancer and autoimmune diseases in the clinical stage. They use their Sareum Kinase Inhibitor Library platform to create small molecule drugs.
Their primary product, SDC-1801, is a TYK2/JAK1 inhibitor currently in Phase 1a clinical trials for autoimmune disease treatment. Additionally, they are working on SDC-1802, another TYK2/JAK1 inhibitor in the preclinical stage for cancer and cancer-immunotherapy applications. They also have SRA737, a clinical-stage Chk1 inhibitor that has completed Phase II clinical trials, targeting cancer cell replication and DNA damage repair.
Established in 2004 and headquartered in Cambridge, United Kingdom, you can find more information about Sareum Holdings plc on their website: https://www.sareum.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
SAR Stock Overview
| Market Cap in USD | 11m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception | 2004-10-11 |
SAR Stock Ratings
| Growth 5y | -1.68 |
| Fundamental | -68.8 |
| Dividend | - |
| Rel. Performance vs Sector | -13.91 |
| Analysts | - |
| Fair Price Momentum | 20.24 GBX |
| Fair Price DCF | - |
SAR Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
SAR Growth Ratios
| Growth 12m | -79.41% |
| Growth Correlation 12m | -89% |
| Growth Correlation 3m | -65% |
| CAGR 5y | -6.22% |
| Sharpe Ratio 12m | -0.77 |
| Alpha vs SP500 12m | -96.55 |
| Beta vs SP500 5y weekly | 0.64 |
| ValueRay RSI | 86.07 |
| Volatility GJR Garch 1y | 347.81% |
| Price / SMA 50 | 6.84% |
| Price / SMA 200 | -55.4% |
| Current Volume | 1894.5k |
| Average Volume 20d | 3639.9k |
External Links for SAR Stock
As of April 29, 2024, the stock is trading at GBX 26.25 with a total of 1,894,483 shares traded.
Over the past week, the price has changed by +12.90%, over one month by +144.19%, over three months by -46.43% and over the past year by -77.07%.
According to ValueRays Forecast Model, SAR Sareum Hldgs Plc will be worth about 22.4 in April 2025. The stock is currently trading at 26.25. This means that the stock has a potential downside of -14.7%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 176 | 570 |
| Analysts Target Price | - | - |
| ValueRay Target Price | 22.4 | -14.7 |